Investigating post Transcriptional Essential Gene Regulation In Leishmania (InTEGRL)
研究利什曼原虫转录后必需基因调控 (InTEGRL)
基本信息
- 批准号:MR/V031511/1
- 负责人:
- 金额:$ 64.89万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2022
- 资助国家:英国
- 起止时间:2022 至 无数据
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Leishmania are the cause of leishmaniasis, the 9th greatest infectious disease burden. Nearly 50% of all patients are children. No vaccine currently exists and epidemics are increasing in occurrence and severity. Treatments have toxic and painful side effects, are inappropriate for children and have growing resistances developing. The single-cell Leishmania transforms into many different forms during its lifecycle to adapt to very different hosts; moving from mammals to sandflies and back to mammals by sandfly bites. Only Leishmania cells of certain lifecycle stage forms can infect and survive in humans. Major changes to the parasite's appearance, metabolism and virulence proteins occur during these transitions that enable them to survive. Leishmania gene expression relies almost exclusively upon mRNA regulation. In response to changes in the environment, specific parasite proteins bind mRNAs and target them for protein production to guide and promote adaptation. Proteins that control the changes these parasites go through enable them to adapt, survive in and infect humans. Such proteins are essential for the virulence and spread of Leishmania infection. By characterising such regulatory proteins and their downstream targets, we can find out what mechanisms Leishmania use to control their lifecycle changes. If we can isolate and stop control panel "Regulator" proteins, we can block Leishmania from establishing an infection in humans. Significant findings would provide insight to leishmaniasis research and related diseases.Leishmania proteins are different from human proteins; therefore we can exploit these differences to target Leishmania-specific developmental regulators, block their function and block the parasites' ability to invade. Recently, the Walrad lab has not only identified the full sets of proteins that bind genes in Leishmania, but from these have found 12 key Leishmania regulator proteins that are essential for cellular survival and infection. The majority of these regulators are pathogen-specific and not present in animals, making these potential druggable targets. We want to find out now how these regulators function; what other proteins and RNAs they bind to enable Leishmania to survive and infect. It is possible these essential Regulators or their cofactors could inform new drug discovery to block Leishmania infection.
利什曼原虫是导致利什曼病的原因,利什曼病是第九大传染病负担。近50%的患者是儿童。目前还没有疫苗,流行病的发生率和严重程度都在增加。治疗有毒性和痛苦的副作用,不适合儿童,并有越来越多的阻力发展。单细胞利什曼原虫在其生命周期中转变为许多不同的形式,以适应不同的宿主;从哺乳动物到白蛉,再通过白蛉叮咬回到哺乳动物。只有某些生命周期阶段形式的利什曼原虫细胞才能感染人类并存活。寄生虫的外观,代谢和毒力蛋白的主要变化发生在这些过渡期间,使它们能够生存。利什曼原虫基因表达几乎完全依赖于mRNA调控。为了应对环境的变化,特定的寄生虫蛋白质结合mRNA并靶向它们产生蛋白质,以指导和促进适应。控制这些寄生虫变化的蛋白质使它们能够适应,在人类中生存并感染人类。这些蛋白质是利什曼原虫感染的毒力和传播所必需的。通过表征这些调节蛋白及其下游靶点,我们可以发现利什曼原虫使用什么机制来控制它们的生命周期变化。如果我们能分离并阻止控制面板“调节器”蛋白,我们就能阻止利什曼原虫在人类中感染。利什曼原虫蛋白质与人类蛋白质不同,因此我们可以利用这些差异来靶向利什曼原虫特异性发育调节因子,阻断其功能并阻断寄生虫的入侵能力。最近,Walrad实验室不仅确定了与利什曼原虫基因结合的全套蛋白质,而且从中发现了12种对细胞存活和感染至关重要的关键利什曼原虫调节蛋白。这些调节剂中的大多数是病原体特异性的,并且不存在于动物中,使得这些潜在的可药用靶标。我们现在想知道这些调节因子是如何发挥作用的;它们结合了哪些其他蛋白质和RNA,使利什曼原虫能够存活和感染。这些重要的调节因子或它们的辅因子可能会为阻止利什曼原虫感染的新药发现提供信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pegine Walrad其他文献
Identification and Stage-specific Association with the Translational Apparatus of <em>Tb</em>ZFP3, a CCCH Protein That Promotes Trypanosome Life-cycle Development
- DOI:
10.1074/jbc.m604280200 - 发表时间:
2006-12-22 - 期刊:
- 影响因子:
- 作者:
Athina Paterou;Pegine Walrad;Paul Craddy;Katelyn Fenn;Keith Matthews - 通讯作者:
Keith Matthews
Pegine Walrad的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pegine Walrad', 18)}}的其他基金
Regulating the trans-regulators: Investigating the PRMT7 molecular pathway as an epigenetic regulator of Leishmania spp. virulence
调节反式调节因子:研究 PRMT7 分子途径作为利什曼原虫属的表观遗传调节因子。
- 批准号:
MR/N017633/1 - 财政年份:2016
- 资助金额:
$ 64.89万 - 项目类别:
Research Grant
Newton001 Biochemical Investigation of the Enzyme PRMT7 Function in Leishmania spp Parasite Infectivity; Screening Targets for Leishmaniasis Relevance
Newton001 利什曼原虫寄生虫感染性中酶 PRMT7 功能的生化研究;
- 批准号:
MR/M02640X/1 - 财政年份:2015
- 资助金额:
$ 64.89万 - 项目类别:
Research Grant
Identifying and Characterising Developmental Regulators of Human Infectious Leishmania
人类传染性利什曼原虫发育调节因子的识别和表征
- 批准号:
MR/L00092X/1 - 财政年份:2013
- 资助金额:
$ 64.89万 - 项目类别:
Research Grant
相似国自然基金
基于可见光环化反应的Post-Iboga类吲哚生物碱不对称集群合成
- 批准号:22361048
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
盐皮质激素受体抑制2型固有淋巴细胞活化加重心肌梗死后心室重构的作用机制
- 批准号:82372202
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
蛋白精氨酸甲基化转移酶PRMT5调控PPARG促进巨噬细胞M2极化及其在肿瘤中作用的机制研究
- 批准号:82371738
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
基于菌群-肠-脑轴研究TMAO通过POST1/SREBP2调节星形胶质细胞胆固醇代谢参与针刺减轻糖尿病认知功能障碍的机制
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
NOD1棕榈酰化修饰通过炎症信号调控胰岛素抵抗的分子机制
- 批准号:32000529
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
CIDE家族蛋白泛素化降解的机制和功能研究
- 批准号:31970707
- 批准年份:2019
- 资助金额:52.0 万元
- 项目类别:面上项目
含21微米和30微米辐射特征的星周包层中的气态分子
- 批准号:11973099
- 批准年份:2019
- 资助金额:63.0 万元
- 项目类别:面上项目
缺氧通过eIF4E2/GSK3β信号通路调控细胞衰老的作用及机制
- 批准号:31970682
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
蛋白质激酶MAPK7参与纤毛组装的功能和分子机理
- 批准号:31972888
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
辅酶A类代谢中间产物参与组蛋白表观遗传修饰调控肝细胞代谢网络对高油脂营养应答的机制研究
- 批准号:91957110
- 批准年份:2019
- 资助金额:83.0 万元
- 项目类别:重大研究计划
相似海外基金
Investigating PUM1 mediated post-transcriptional regulation of human hemoglobin switching and erythropoiesis
研究 PUM1 介导的人血红蛋白转换和红细胞生成的转录后调节
- 批准号:
10568059 - 财政年份:2023
- 资助金额:
$ 64.89万 - 项目类别:
Investigating post-transcriptional control networks that regulate mammalian oogenesis
研究调节哺乳动物卵子发生的转录后控制网络
- 批准号:
559065-2021 - 财政年份:2022
- 资助金额:
$ 64.89万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Investigating post-transcriptional gene regulation in cancer
研究癌症转录后基因调控
- 批准号:
nhmrc : 1196405 - 财政年份:2021
- 资助金额:
$ 64.89万 - 项目类别:
Investigator Grants
Investigating post-transcriptional control networks that regulate mammalian oogenesis
研究调节哺乳动物卵子发生的转录后控制网络
- 批准号:
559065-2021 - 财政年份:2021
- 资助金额:
$ 64.89万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Investigating Circadian Post-Transcriptional Regulation.
研究昼夜节律转录后调节。
- 批准号:
10228665 - 财政年份:2018
- 资助金额:
$ 64.89万 - 项目类别:
Investigating Circadian Post-Transcriptional Regulation.
研究昼夜节律转录后调节。
- 批准号:
10621067 - 财政年份:2018
- 资助金额:
$ 64.89万 - 项目类别:
Investigating Circadian Post-Transcriptional Regulation.
研究昼夜节律转录后调节。
- 批准号:
10372273 - 财政年份:2018
- 资助金额:
$ 64.89万 - 项目类别:
Investigating Circadian Post-Transcriptional Regulation.
研究昼夜节律转录后调节。
- 批准号:
10454368 - 财政年份:2018
- 资助金额:
$ 64.89万 - 项目类别:
Investigating Transcriptional and Post-transcriptional Regulation of dE2F1 Expression during Drosophila Development
研究果蝇发育过程中 dE2F1 表达的转录和转录后调控
- 批准号:
RGPIN-2014-03678 - 财政年份:2018
- 资助金额:
$ 64.89万 - 项目类别:
Discovery Grants Program - Individual
Investigating Transcriptional and Post-transcriptional Regulation of dE2F1 Expression during Drosophila Development
研究果蝇发育过程中 dE2F1 表达的转录和转录后调控
- 批准号:
RGPIN-2014-03678 - 财政年份:2017
- 资助金额:
$ 64.89万 - 项目类别:
Discovery Grants Program - Individual